Drug
Azd4512 Monotherapy
Azd4512 Monotherapy: highest development phase Phase 1/2, developed by AstraZeneca. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| AZD4512 monotherapy NCT07109219 | Phase 1/2 | B-cell Acute Lymphoblastic Leukemia (B-ALL) |
Latest
No recent events.
Follow Azd4512 Monotherapy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.